Clinical efficacy and safety of oral terbinafine in fungal mycetoma.

Objectives: An open-label study was performed to assess the efficacy and safety of terbinafine in the treatment of eumycetoma.

Methods: Single-center, open-label study, including 27 patients with signs and symptoms of eumycetoma which had developed within 5 years and was confirmed by mycological examination. The intention-to-treat population (n=23) received 500 mg of terbinafine bid for 24-48 weeks.